Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question

PURPOSE: Whether or not androgen receptor (AR) axis could still be targetable in castration resistant prostate cancer (CRPC) patients with disease progression to next generation hormonal agents (NGHAs) is a controversial issue. RESULTS: Serum testosterone in CRPC patients has a positive prognostic r...

Descripción completa

Detalles Bibliográficos
Autores principales: Caramella, Irene, Dalla Volta, Alberto, Bergamini, Marco, Cosentini, Deborah, Valcamonico, Francesca, Berruti, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637055/
https://www.ncbi.nlm.nih.gov/pubmed/35986139
http://dx.doi.org/10.1007/s12020-022-03166-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637055/
https://www.ncbi.nlm.nih.gov/pubmed/35986139
http://dx.doi.org/10.1007/s12020-022-03166-w

Ejemplares similares